| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mikkel Bring Christense. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Danish medical journal. vol 63. issue 4. 2017-01-09. PMID:27034187. |
the overall aim of this phd thesis was to investigate how the blood glucose level affects the glucagon and insulin responses to gip in healthy subjects (study 1) and patients with type 2 diabetes (study 2), and more specifically to investigate the effects of gip and glp-1 at low blood glucose in patients with type 1 diabetes without endogenous insulin secretion (study 3). |
2017-01-09 |
2023-08-13 |
human |
| Yasuo Takeda, Ryuji Ikeda, Tomoko Kond. [Incretin as a Novel Treatment Strategy for NAFLD/NASH]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 136. issue 4. 2017-01-09. PMID:27040341. |
two incretin hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), stimulate glucose-mediated insulin production in pancreatic β cells. |
2017-01-09 |
2023-08-13 |
Not clear |
| Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow, Filip Krag Knop, Sten Madsbad, Henrik Ullits Anderse. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology. vol 4. issue 3. 2017-01-06. PMID:26656289. |
the combination of insulin and glucagon-like peptide-1 (glp-1) receptor agonist therapy improves glycaemic control, induces weight loss, and reduces insulin dose needed in type 2 diabetes. |
2017-01-06 |
2023-08-13 |
Not clear |
| Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow, Filip Krag Knop, Sten Madsbad, Henrik Ullits Anderse. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology. vol 4. issue 3. 2017-01-06. PMID:26656289. |
we assessed the efficacy and safety of the glp-1 receptor agonist liraglutide as an add-on therapy to insulin for overweight adult patients with type 1 diabetes. |
2017-01-06 |
2023-08-13 |
Not clear |
| James G Johnson, Jennifer N Langan, Chen Gilo. TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE. Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians. vol 47. issue 3. 2017-01-06. PMID:27691959. |
insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (glp-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. |
2017-01-06 |
2023-08-13 |
Not clear |
| Madeleine M Fletcher, Michelle L Halls, Arthur Christopoulos, Patrick M Sexton, Denise Wootte. The complexity of signalling mediated by the glucagon-like peptide-1 receptor. Biochemical Society transactions. vol 44. issue 2. 2016-12-30. PMID:27068973. |
the receptor is activated by the incretin peptide glp-1 promoting a broad range of physiological effects including glucose-dependent insulin secretion and biosynthesis, improved insulin sensitivity of peripheral tissues, preservation of β-cell mass and weight loss, all of which are beneficial in the treatment of type 2 diabetes. |
2016-12-30 |
2023-08-13 |
Not clear |
| R E Steinert, C Beglinger, W Langhan. Intestinal GLP-1 and satiation: from man to rodents and back. International journal of obesity (2005). vol 40. issue 2. 2016-12-28. PMID:26315842. |
glp-1 potentiates glucose-induced insulin secretion, suppresses glucagon release, slows gastric emptying and may serve as a satiation signal, although the physiological status of the latter function has not been fully established yet. |
2016-12-28 |
2023-08-13 |
Not clear |
| Daniel Vallöf, Paola Maccioni, Giancarlo Colombo, Minja Mandrapa, Julia Winsa Jörnulf, Emil Egecioglu, Jörgen A Engel, Elisabet Jerlha. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addiction biology. vol 21. issue 2. 2016-12-20. PMID:26303264. |
the incretin hormone, glucagon-like peptide 1 (glp-1), regulates gastric emptying, glucose-dependent stimulation of insulin secretion and glucagon release, and glp-1 analogs are therefore approved for treatment of type ii diabetes. |
2016-12-20 |
2023-08-13 |
mouse |
| Michelle DeGeeter, Bobbie Williamso. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. Journal of pharmacy practice. vol 29. issue 2. 2016-12-16. PMID:25312263. |
alternative agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, glp-1 agonists, dpp-iv inhibitors, and sglt-2 inhibitors. |
2016-12-16 |
2023-08-13 |
Not clear |
| Pernilla Huetson, James L Palmer, Andrée Levorsen, Marie Fournier, Maeva Germe, Euan McLeo. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. Journal of medical economics. vol 18. issue 8. 2016-12-13. PMID:25853868. |
cost-effectiveness of once daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in norway. |
2016-12-13 |
2023-08-13 |
Not clear |
| Catherine E Moss, Leslie L Glass, Eleftheria Diakogiannaki, Ramona Pais, Carol Lenaghan, David M Smith, Marianne Wedin, Mohammad Bohlooly-Y, Fiona M Gribble, Frank Reiman. Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells. Peptides. vol 77. 2016-12-13. PMID:26144594. |
glucagon-like peptide-1 (glp-1) is an incretin hormone derived from proglucagon, which is released from intestinal l-cells and increases insulin secretion in a glucose dependent manner. |
2016-12-13 |
2023-08-13 |
Not clear |
| Paul Richards, Ramona Pais, Abdella M Habib, Cheryl A Brighton, Giles S H Yeo, Frank Reimann, Fiona M Gribbl. High fat diet impairs the function of glucagon-like peptide-1 producing L-cells. Peptides. vol 77. 2016-12-13. PMID:26145551. |
glucagon-like peptide-1 (glp-1) acts as a satiety signal and enhances insulin release. |
2016-12-13 |
2023-08-13 |
Not clear |
| Claire L Meek, Hannah B Lewis, Frank Reimann, Fiona M Gribble, Adrian J Par. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. vol 77. 2016-12-13. PMID:26344355. |
the aim of this review is to summarise the effects of different bariatric surgery procedures upon gastrointestinal and pancreatic peptides, including ghrelin, gastrin, cholecystokinin (cck), glucose-dependent insulinotropic hormone (gip), glucagon-like peptide 1 (glp-1), peptide yy (pyy), oxyntomodulin, insulin, glucagon and somatostatin. |
2016-12-13 |
2023-08-13 |
Not clear |
| Matthew J Armstrong, Diana Hull, Kathy Guo, Darren Barton, Jonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, Jinglei Yu, Stephen C Gough, Philip N Newsome, Jeremy W Tomlinso. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of hepatology. vol 64. issue 2. 2016-12-13. PMID:26394161. |
this study determined the effect of a long-acting glp-1 analogue, liraglutide, on organ-specific insulin sensitivity, hepatic lipid handling and adipose dysfunction in biopsy-proven nash. |
2016-12-13 |
2023-08-13 |
Not clear |
| Stefanie Amarens de Boer, Joop Daniel Lefrandt, Japke Frida Petersen, Hendrikus Hessel Boersma, Douwe Johannes Mulder, Klaas Hoogenber. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. International journal of clinical pharmacy. vol 38. issue 1. 2016-12-13. PMID:26597956. |
glucagon-like peptide-1 receptor agonists (glp-1 ra) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. |
2016-12-13 |
2023-08-13 |
Not clear |
| Ki-Suk Kim, Hea Jung Yang, In-Seung Lee, Kang-Hoon Kim, Jiyoung Park, Hyeon-Soo Jeong, Yoomi Kim, Kwang Seok Ahn, Yun-Cheol Na, Hyeung-Jin Jan. The aglycone of ginsenoside Rg3 enables glucagon-like peptide-1 secretion in enteroendocrine cells and alleviates hyperglycemia in type 2 diabetic mice. Scientific reports. vol 5. 2016-12-13. PMID:26675132. |
rg3, a ginsenoside metabolite that transformed the structure through a steaming process, showed the strongest glp-1 secreting effects in nci-h716 cells and also showed an anti-hyperglycemic effect on a type 2 diabetic mouse model through increased plasma glp-1 and plasma insulin levels during an oral glucose tolerance test. |
2016-12-13 |
2023-08-13 |
mouse |
| Signe Tellerup Nielsen, Nina Majlund Harder-Lauridsen, Fabiana Braga Benatti, Anne-Sophie Wedell-Neergaard, Mark Preben Lyngbæk, Kirsten Møller, Bente Klarlund Pedersen, Rikke Krogh-Madse. The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers. Journal of applied physiology (Bethesda, Md. : 1985). vol 120. issue 6. 2016-12-13. PMID:26679616. |
blood glucose, serum insulin, serum c-peptide, plasma incretin hormones [glucagon-like peptide (glp-1) and glucose-dependent insulinotropic peptide (gip)], and serum glucagon were measured serially during both the ogtt and the ivgi. |
2016-12-13 |
2023-08-13 |
human |
| Signe Tellerup Nielsen, Nina Majlund Harder-Lauridsen, Fabiana Braga Benatti, Anne-Sophie Wedell-Neergaard, Mark Preben Lyngbæk, Kirsten Møller, Bente Klarlund Pedersen, Rikke Krogh-Madse. The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers. Journal of applied physiology (Bethesda, Md. : 1985). vol 120. issue 6. 2016-12-13. PMID:26679616. |
concentrations of glucose, insulin, c-peptide, and gip measured during the ogtt were higher after the bed rest intervention (all p < 0.05), whereas there was no difference in the levels of glp-1 and glucagon. |
2016-12-13 |
2023-08-13 |
human |
| Rachel T McGrath, Samantha L Hocking, Miriam Priglinger, Susan Day, Geoffrey K Herkes, Martin Krause, Gregory R Fulche. Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. BMJ open. vol 6. issue 2. 2016-12-13. PMID:26911582. |
owing to their glucose-dependent mechanism of action, glp-1 analogues are associated with a low risk of hypoglycaemia, which may give them an advantage over intensive insulin therapy in the acute management of hyperglycaemia in this setting. |
2016-12-13 |
2023-08-13 |
Not clear |
| Jen-Hung Huang, Yao-Chang Chen, Ting-I Lee, Yu-Hsun Kao, Tze-Fan Chazo, Shih-Ann Chen, Yi-Jen Che. Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes. Peptides. vol 78. 2016-12-13. PMID:26930508. |
glucagon like-peptide-1 (glp-1) is an incretin hormone with antidiabetic effects through stimulating insulin secretion, β cell neogenesis, satiety sensation, and inhibiting glucagon secretion. |
2016-12-13 |
2023-08-13 |
Not clear |